A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.
Keep Reading
A closer look at the tech, AI, and open ecosystem behind Tien Kung 3.0’s real-world push
Updated
February 18, 2026 8:03 PM
Humanoid robots working in a warehouse. PHOTO: ADOBE STOCK
Humanoid robotics has advanced quickly in recent years. Machines can now walk, balance, and interact with their surroundings in ways that once seemed out of reach. Yet most deployments remain limited. Many robots perform well in controlled settings but struggle in real-world environments. Integration is often complex, hardware interfaces are closed, software tools are fragmented, and scaling across industries remains difficult.
Against this backdrop, X-Humanoid has introduced its latest general-purpose platform, Embodied Tien Kung 3.0. The company positions it not simply as another humanoid robot, but as a system designed to address the practical barriers that have slowed adoption, with a focus on openness and usability.
At the hardware level, Embodied Tien Kung 3.0 is built for mobility, strength, and stability. It is equipped with high-torque integrated joints that provide strong limb force for high-load applications. The company says it is the first full-size humanoid robot to achieve whole-body, high-dynamic motion control integrated with tactile interaction. In practice, this means the robot is designed to maintain balance and execute dynamic movements even in uneven or cluttered environments. It can clear one-meter obstacles, perform consecutive high-dynamic maneuvers, and carry out actions such as kneeling, bending, and turning with coordinated whole-body control.
Precision is also a focus. Through multi-degree-of-freedom limb coordination and calibrated joint linkage, the system is designed to achieve millimeter-level operational accuracy. This level of control is intended to support industrial-grade tasks that require consistent performance and minimal error across changing conditions.
But hardware is only part of the equation. The company pairs the robot with its proprietary Wise KaiWu general-purpose embodied AI platform. This system supports perception, reasoning, and real-time control through what the company describes as a coordinated “brain–cerebellum” architecture. It establishes a continuous perception–decision–execution loop, allowing the robot to operate with greater autonomy and reduced reliance on remote control.
For higher-level cognition, Wise KaiWu incorporates components such as a world model and vision-language models (VLM) to interpret visual scenes, understand language instructions, and break complex objectives into structured steps. For real-time execution, a vision-language-action (VLA) model and full autonomous navigation system manage obstacle avoidance and precise motion under variable conditions. The platform also supports multi-agent collaboration, enabling cross-platform compatibility, asynchronous task coordination, and centralized scheduling across multiple robots.
A central part of the platform is openness. The company states that the system is designed to address compatibility and adaptation challenges across both development and deployment layers. On the hardware side, Embodied Tien Kung 3.0 includes multiple expansion interfaces that support different end-effectors and tools, allowing faster adaptation to industrial manufacturing, specialized operations, and commercial service scenarios. On the software side, the Wise KaiWu ecosystem provides documentation, toolchains, and a low-code development environment. It supports widely adopted communication standards, including ROS2, MQTT, and TCP/IP, enabling partners to customize applications without rebuilding core systems.
The company also highlights its open-source approach. X-Humanoid has open-sourced key components from the Embodied Tien Kung and Wise KaiWu platforms, including the robot body architecture, motion control framework, world model, embodied VLM and cross-ontology VLA models, training toolchains, the RoboMIND dataset, and the ArtVIP simulation asset library. By opening access to these elements, the company aims to reduce development costs, lower technical barriers, and encourage broader participation from researchers, universities, and enterprises.
Embodied Tien Kung 3.0 enters a market where technical progress is visible but large-scale adoption remains uneven. The gap is not only about movement or strength. It is about integration, interoperability, and the ability to operate reliably and autonomously in everyday industrial and commercial settings. If platforms can reduce fragmentation and simplify deployment, humanoid robots may move beyond demonstrations and into sustained commercial use.
In that sense, the significance of Embodied Tien Kung 3.0 lies less in isolated technical claims and more in how its high-dynamic hardware, embodied AI system, open interfaces, and collaborative architecture are structured to work together. Whether that integrated approach can close the deployment gap will shape how quickly humanoid robotics becomes part of real-world operations.